Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment published : This year save search
Genentech’s ALK Inhibitor First Adjuvant Treatment for ALK-Positive, Early NSCLC
Published: 2024-04-19 (Crawled : 15:00) - biospace.com/
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: -0.4%
H: 3.01%
C: 2.94%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.83%
H: 1.35%
C: 1.2%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.39%
H: 1.69%
C: 1.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.83%
H: 1.83%
C: 0.89%
first treatment for
Health Canada Approves KEYTRUDA as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma
Published: 2024-04-19 (Crawled : 13:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.22%
H: 0.37%
C: 0.1%
health treatment for canada advanced keytruda
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 02:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.23%
H: 0.61%
C: 0.46%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.83%
H: 1.83%
C: 0.89%
MIRM | News | $23.83 1.1% 1.09% 340K
|
Health Technology
|
| O: -0.68%
H: 2.52%
C: 1.71%
report million reach treatment market
California Water Service Group Moving Forward to Install PFAS Treatment Despite CPUC Dismissal of Request to Track Capital Costs in Pre-Approved Memorandum Account
Published: 2024-04-18 (Crawled : 21:00) - globenewswire.com
CWT | $45.79 1.98% 0.0% 710K
|
Utilities
|
| O: 0.9%
H: 2.19%
C: 2.19%
water california service group treatment
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 4.91%
H: 11.36%
C: 0.67%
drug treatment designation for grants leukemia
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
| Email alert
Add to watchlist
onct-534 first cancer treatment for study
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
Published: 2024-04-18 (Crawled : 13:00) - biospace.com/
EVO | $7.15 -0.7% 19K
|
Manufacturing
|
| O: 0.42%
H: 0.0%
C: 0.0%
partnership fibrosis
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.46 -1.21% -1.22% 21K
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
dm199 first stroke treatment for trial therapeutics
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Published: 2024-04-17 (Crawled : 13:00) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 2.68%
H: 3.48%
C: -11.3%
treatment biopharma royalties global for agreement
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Published: 2024-04-17 (Crawled : 12:00) - prnewswire.com
NRBO | $3.325 -3.34% -3.46% 21K
|
Health Technology
|
| O: 8.53%
H: 0.0%
C: -6.23%
da-1726 obesity first treatment pharmaceuticals for trial
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
GENE 1 d | $2.27 -6.97% -7.49% 64K
|
Health Technology
|
| O: 3.47%
H: 0.0%
C: -3.66%
precision treatment
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
CMND | $1.22 3.56% 3.43% 110K
|
n/a
|
| O: -0.82%
H: 0.0%
C: 0.0%
disorders treatment for agreement
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
Prostate Cancer: Advancements in Prevention and Treatment Drive Global Market Growth
Published: 2024-04-17 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
treatment global growth market
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Published: 2024-04-17 (Crawled : 06:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.87%
H: 0.16%
C: -0.59%
kesimpta sclerosis novartis show benefits
Fracking Water Treatment Market size to record USD 1.20 billion growth from 2023-2027, Adoption of supercritical carbon in fracking is one of the key market trends, Technavio
Published: 2024-04-16 (Crawled : 23:00) - prnewswire.com
XYL | $127.84 0.53% 0.0% 2.2M
|
Producer Manufacturing
|
| O: 0.38%
H: 0.0%
C: -1.77%
water one treatment key growth market
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M
|
| Email alert
Add to watchlist
au8 neurology sclerosis treatment for meeting
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain
Published: 2024-04-16 (Crawled : 16:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -1.47%
H: 2.05%
C: -0.59%
nulibry authorization treatment for therapeutics
Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
Published: 2024-04-16 (Crawled : 15:00) - biospace.com/
PPCB | $0.001 -41.86% 11M
|
Manufacturing
|
| O: 0.0%
H: 14.29%
C: -7.14%
patent cancer biopharma for grant
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Published: 2024-04-16 (Crawled : 14:00) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: -1.24%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
PHG | $19.98 0.0% 540K
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.19%
H: 0.52%
C: -0.17%
VRNA | $15.82 -1.74% -1.83% 640K
|
Health Technology
|
| O: 1.65%
H: 2.43%
C: 0.87%
reach treatment research market
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.